· An update on dose selection and interim blinded safety results from varoglutamstat´s Phase 2b study (VIVIAD) will be presented Halle (Saale) / Munich, Germany, November 28, 2022 – Vivoryon Therapeutics […]
Do you like it?
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Listing of additional […]
Do you like it?
HALLE (SAALE) / MUNICH, GERMANY, November 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule […]
Do you like it?
HALLE (SAALE) / MUNICH, GERMANY, November 14, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small […]
Do you like it?
HALLE (SAALE) / MUNICH, GERMANY, September 30, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule […]
Do you like it?
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Significant commitment from […]
Do you like it?
HALLE (SAALE) / MUNICH, GERMANY, September 26, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small […]
Do you like it?
Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA Therapeutic dose of 600 mg varoglutamstat given twice daily selected by […]
Do you like it?
Data underscore the unique potential of Vivoryon’s N3pE-focused strategy in mono- and combination therapy settings in AD Combination treatment of aducanumab and varoglutamstat achieves additive effect […]
Do you like it?